^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    1d
    Refleeve: The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy (clinicaltrials.gov)
    P=N/A, N=100, Completed, Centre Hospitalier Universitaire de Nice | Recruiting --> Completed
    Trial completion
    1d
    TFLAG: TAIC FOLFOX for Locally Advanced G/GEJA (clinicaltrials.gov)
    P2, N=31, Recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    New P2 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    Identification of protein lysine lactylation and potential targets in esophageal squamous cell carcinoma. (PubMed, Transl Cancer Res)
    The study found a positive correlation between Kla and ESCC metastasis. Furthermore, ENO1-Kla potentially promotes esophageal cancer (EC) metastasis and it may be a promising treatment target and a predictive biomarker of ESCC metastasis.
    Journal
    |
    ENO1 (Enolase 1)
    1d
    Parimifasor elicits broad-spectrum antitumor effects by suppressing the expression of oncogenic genes. (PubMed, Transl Cancer Res)
    Integration with TCGA data identified 10 oncogenic genes (PARP10, OAS1, OAS3, PRR4, ZNFX1, HELZ2, SP110, CSRNP1, DDX3L, and PARP14) dysregulated across 20+ cancer types; qPCR confirmed their consistent downregulation posttreatment in both cell lines (P<0.05). This study establishes parimifasor's antitumor efficacy via the suppression of immune pathway-associated oncogenes, supporting its repurposing as a cancer therapeutic agent and providing biomarker candidates for clinical development.
    Journal • PARP Biomarker • IO biomarker
    |
    NLRC5 (NLR Family CARD Domain Containing 5) • PARP10 (Poly(ADP-Ribose) Polymerase Family Member 10)
    1d
    Narrative review: clinical application and challenges of circulating tumor DNA in treatment response evaluation and prognostic prediction for esophageal cancer. (PubMed, J Thorac Dis)
    Future integration with multi-omics data, radiomics, and artificial intelligence (AI) promises to enhance its clinical utility. Overcoming current hurdles through standardization and technological innovation is essential for its routine clinical adoption.
    Review • Journal • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    TP53 mutation • PTEN mutation
    1d
    D9803C00001: A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus. (2024-519787-40-00)
    P2/3, N=126, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    1d
    GS-US-742-7757: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (2025-524095-27-00)
    P1/2, N=45, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    1d
    Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus (clinicaltrials.gov)
    P=N/A, N=600, Active, not recruiting, Johns Hopkins University | Trial completion date: Jun 2026 --> Aug 2026
    Trial completion date
    1d
    ESCC-PT: Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2/3 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Gilotrif (afatinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • AiRuiKang (dalpiciclib)
    2d
    Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Sun Yat-sen University | Completed --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial completion date
    2d
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    2d
    The tumor-microenvironment-associated prognostic gene TIGIT promotes malignant phenotypes in esophageal carcinoma. (PubMed, Transl Oncol)
    TIGIT, along with PD-L1 and CD163, is a potential prognostic marker for resectable ESCC. TIGIT is not only expressed in immune cells but also in ESCC tumor cells, suggesting its potential as a biomarker and therapeutic target. Further mechanistic studies are warranted to elucidate the downstream signaling pathways and validate the mechanisms of TIGIT in ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)